Anuh Pharma Limited , a prominent player in the pharmaceutical industry, held its 65th Annual General Meeting (AGM) on August 22, 2025, marking a significant milestone in the company's governance and strategic direction. The shareholders approved several key appointments and reappointments, reinforcing the company's leadership structure and compliance mechanisms.

Leadership Continuity and Experience

The AGM saw the reappointment of two Non-Executive Non-Independent Directors, Mr. Bharat Nemchand Shah and Mr. Gaurav Satish Shah. Mr. Bharat Shah brings a wealth of experience to the board with five decades in the pharmaceutical industry, while Mr. Gaurav Shah contributes 20 years of industry expertise, backed by a Bachelor's degree in Engineering from the USA and a Diploma in Family Managed Business Administration.

Joint Managing Directors Reappointed

In a move that ensures leadership stability, the shareholders approved the reappointment of Mr. Ritesh Shah and Mr. Vivek Shah as Joint Managing Directors for a five-year term from January 8, 2026, to January 7, 2031. Mr. Ritesh Shah, with 21 years of pharmaceutical experience, specializes in marketing, finance, business strategy, and sourcing. Mr. Vivek Shah, bringing over 15 years of experience, focuses on operations, R&D, and regulatory affairs.

Strengthening Audit and Compliance

The AGM also addressed key audit appointments:

1. Mr. Ankit Kishor Chande was reappointed as Cost Auditor for the financial year ending March 2026. With over 12 years of experience across 17 industries, Chande brings valuable expertise to Anuh Pharma's cost management processes.

2. M/s. GHV & Co., Practicing Company Secretaries, secured a five-year appointment as Secretarial Auditor from FY 2025-26 to FY 2029-30. The firm's extensive experience in secretarial compliance and corporate governance will support Anuh Pharma's regulatory adherence.

Shareholder Approval and Voting Results

The scrutinizer's report revealed overwhelming shareholder support for all resolutions presented at the AGM. Key appointments and reappointments received over 99.99% votes in favor, demonstrating strong shareholder confidence in the company's leadership and governance choices.

Dividend Declaration

In a positive move for shareholders, the AGM approved a dividend of Rs. 1.50 per equity share of face value Rs. 5 for the Financial Year 2024-25, reflecting the company's commitment to delivering value to its investors.

Anuh Pharma's 65th AGM decisions reflect a balance between continuity and compliance, positioning the company for sustained growth in the dynamic pharmaceutical sector. The reappointment of experienced leaders and the engagement of specialized auditors underscore the company's focus on strong governance and strategic direction.

Anuh Pharma Limited, a prominent player in the pharmaceutical industry, has announced its financial results for the first quarter, alongside a key executive appointment.

Financial Performance

The company reported a significant increase in revenue from operations for Q1, reaching Rs 18,647.94 lakhs, up from Rs 13,790.83 lakhs in the same quarter of the previous year, marking a 35.2% year-over-year growth. However, the profit after tax saw a slight decline, standing at Rs 830.12 lakhs compared to Rs 950.91 lakhs in the corresponding quarter last year.

Key financial highlights for Q1:

The company's EBITDA margin for the quarter stood at 7.34%, showing a decrease from 10.36% in the same quarter of the previous year. This decline in profitability metrics despite revenue growth suggests increased operational costs or market pressures during the quarter.

Appointment of Chief Marketing Officer

In a strategic move to strengthen its leadership team, Anuh Pharma's Board of Directors has approved the appointment of Mr. Vinayak Shenoy as the Chief Marketing Officer, effective August 11, 2025. Mr. Shenoy brings over 15 years of experience in APIs and Intermediates, with expertise spanning global markets including the USA, Europe, CIS, SEA, LATAM, and India.

Mr. Shenoy's appointment is expected to bolster Anuh Pharma's market presence and strategic growth initiatives. His extensive background in business development and sales, coupled with his proven track record in key account management and market-entry strategies, aligns well with the company's expansion goals.

Looking Ahead

As Anuh Pharma navigates the evolving pharmaceutical landscape, the combination of revenue growth and strategic appointments suggests a focus on both immediate performance and long-term market positioning. Investors and industry observers will likely keep a close watch on how these developments translate into sustained financial performance and market share growth in the coming quarters.

The company continues to operate in the Bulk drug and Chemicals segment, as identified in its financial reporting, maintaining its focus on its core business areas.

Anuh Pharma Limited remains committed to creating value for its stakeholders through operational excellence and strategic initiatives in the pharmaceutical sector.